Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:11:54.368Z.
Calculation as of: 2026-10-06T17:11:54.368Z.
Quote observation: 2026-10-06T17:04:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ae4e4394aaeb0d5c8b7c6b49623c27b4c6984d6a5511a37bd4b8ffeab1df45fa
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$6.90M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $6.90M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.82M | 9.45 | 10.26 | 6.86 | 4.99 |
| Exicure, Inc. (XCUR)vs › | $6.82M | N/A | 116.18 | 43.44 | 55.80 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | 1.49 | 1.62 | 2.80 | 25.96 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.00M | 22.20 | 20.17 | 15.94 | 138.16 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.08M | N/A | 1060.01 | 1293.00 | 2117.95 |
| Aclarion, Inc. (ACON)vs › | $6.66M | 79.48 | 55.12 | 28.27 | 58.64 |
| Biomerica, Inc. (BMRA)vs › | $6.54M | 1.47 | 1.51 | 10.02 | 17.31 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.53M | N/A | 8.07 | 5.46 | 11.12 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-17 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
